Skip to main content
AKBA
NASDAQ Life Sciences

Vadadustat Hits Non-Inferiority Endpoint in VOCAL, Backing Three-Times-Weekly Dosing

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.693
Mkt Cap
$192.506M
52W Low
$0.542
52W High
$2.145
52W Position info
28% above low
Off High info
68% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

AKBA sits 28% above its 52-week low of $0.542.

Summary

Akebia's VOCAL trial met its primary endpoint: three-times-weekly vadadustat was non-inferior to ESA (Mircera) in maintaining hemoglobin in 353 in-center hemodialysis patients. The least squares mean Hb difference was -0.45 g/dL with a 95% CI of -0.71 to -0.19, clearing the -0.75 g/dL non-inferiority margin, and treatment-emergent serious adverse event rates were similar (159.7 vs 183.9 events per 100 patient-years). This follows the October 26 presentation of VOICE data showing a hospitalization-driven safety benefit versus Epogen, building a comparative dataset against multiple ESAs. The commercial relevance is dosing convenience: Vafseo is currently approved and marketed as once-daily, and a TIW regimen could fit in-center dialysis workflows, though it remains investigational and would require an FDA label expansion. The company is small and posted a 3Q loss of $14.4 million with Auryxia facing generic erosion, so Vafseo label expansion is the main growth lever; note the October 23 Nasdaq notice that shares closed below $1.00 for 30 consecutive business days, with until April to regain compliance.

At the time of this announcement, AKBA was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.5M. The 52-week trading range was $0.54 to $2.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

AKBA - Latest Insights

AKBA
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.4739
Real-time Price: $0.399 info
Change: -$0.0749 (-16%) info
Market Cap: $107.039M info
AKBA
Nov 05, 2026, 7:37 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.5199
Real-time Price: $0.399 info
Change: -$0.1209 (-23%) info
Market Cap: $107.039M info
AKBA
Nov 05, 2026, 7:10 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.69337
Real-time Price: $0.399 info
Change: -$0.29437 (-42%) info
Market Cap: $107.039M info
AKBA
Oct 26, 2026, 9:20 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.5765
Real-time Price: $0.399 info
Change: -$0.1775 (-31%) info
Market Cap: $107.039M info
AKBA
Oct 23, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5745
Real-time Price: $0.399 info
Change: -$0.1755 (-31%) info
Market Cap: $107.039M info